Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Hettel and Sharifi discuss how germlineHSD3B1 1245A>C variant status influences outcomes of men with prostate cancer receiving androgen deprivation therapy, indicating its utility as a predictive biomarker. Metabolic effects of variant HSD3B1status highlight a potential requirement to modify current treatment frameworks.
Outcomes of patients with high-risk, localized renal cancer depend on optimal patient stratification, surgical management, and systemic therapy selection. Blick et al. discuss the current knowledge on these topics and provide an overview of interventions that are currently being investigated in clinical trials.